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Abstract: PURPOSE The length of time a critically ill coronavirus disease 2019 (COVID-19) patient
remains infectious and should therefore be isolated remains unknown. This prospective study was un-
dertaken in critically ill patients to evaluate the reliability of single negative real-time polymerase chain
reaction (RT-PCR) in lower tracheal aspirates (LTA) in predicting a second negative test and to analyze
clinical factors potentially influencing the viral shedding. METHODS From April 9, 2020 onwards, in-
tubated COVID-19 patients treated in the intensive care unit were systematically evaluated for severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by RT-PCR of nasopharyngeal swabs and LTA.
The time to negativity was defined as the time between the onset of symptoms and the viral clearance in
LTA. In order to identify risk factors for prolonged viral shedding, we used univariate and multivariate
Cox proportional hazards models. RESULTS Forty-eight intubated SARS-CoV-2 patients were enrolled.
Overall, we observed that the association of the first negative RT-PCR with a second negative result was
96.7%. Median viral shedding was 25 (IQR: 21.5-28) days since symptoms’ onset. In the univariate Cox
model analysis, type 2 diabetes mellitus was associated with a prolonged viral RNA shedding (hazard
ratio [HR]: 0.41, 95% CI: 0.06-3.11, p = 0.04). In the multivariate Cox model analysis, type 2 diabetes
was associated with a prolonged viral RNA shedding (HR: 0.31, 95% CI: 0.11-0.89, p = 0.029). CONCLU-
SION Intubated patients with type 2 diabetes mellitus may have prolonged SARS-CoV-2 shedding. In
critically ill COVID-19 patients, one negative LTA should be sufficient to assess and exclude infectivity.
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Abstract
Purpose The length of time a critically ill coronavirus disease 2019 (COVID-19) patient remains infectious and should
therefore be isolated remains unknown. This prospective study was undertaken in critically ill patients to evaluate the
reliability of single negative real-time polymerase chain reaction (RT-PCR) in lower tracheal aspirates (LTA) in predicting a
second negative test and to analyze clinical factors potentially influencing the viral shedding.
Methods From April 9, 2020 onwards, intubated COVID-19 patients treated in the intensive care unit were systematically
evaluated for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by RT-PCR of nasopharyngeal swabs and
LTA. The time to negativity was defined as the time between the onset of symptoms and the viral clearance in LTA. In order
to identify risk factors for prolonged viral shedding, we used univariate and multivariate Cox proportional hazards models.
Results Forty-eight intubated SARS-CoV-2 patients were enrolled. Overall, we observed that the association of the first
negative RT-PCR with a second negative result was 96.7%. Median viral shedding was 25 (IQR: 21.5–28) days since
symptoms’ onset. In the univariate Cox model analysis, type 2 diabetes mellitus was associated with a prolonged viral RNA
shedding (hazard ratio [HR]: 0.41, 95% CI: 0.06–3.11, p= 0.04). In the multivariate Cox model analysis, type 2 diabetes
was associated with a prolonged viral RNA shedding (HR: 0.31, 95% CI: 0.11–0.89, p= 0.029).
Conclusion Intubated patients with type 2 diabetes mellitus may have prolonged SARS-CoV-2 shedding. In critically ill
COVID-19 patients, one negative LTA should be sufficient to assess and exclude infectivity.
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Treatment of critically ill coronavirus disease 2019
(COVID-19) patients requires strict isolation to limit
nosocomial spread of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). However, to date, the length
of time an individual infected with SARS-CoV-2 remains
infectious and needs to be isolated remains unknown, as
viral shedding has been described to persist for an interval
varying between 10 [1] and 60 days [2] after symptoms’
onset. Mild cases may have an earlier viral clearance (i.e.,
negative real-time polymerase chain reaction (RT-PCR) or
cell cultures by day 10 post onset) [1, 3], whereas severe
cases may have longer viral shedding [4, 5]. Most studies
focused on nasopharyngeal or oropharyngeal swabs
[3, 4, 6–9] and did not consider lower respiratory samples.
Most importantly in this context, only one study (until June
2020) assessed the infectivity with cell culture for SARS-
CoV-2 [1].
This prospective study was undertaken in critically ill
patients to (1) evaluate the reliability of single negative RT-
PCR in predicting a second negative test, (2) investigate the
interval from symptoms’ onset to RT-PCR negativity, and
(3) analyze clinical factors potentially influencing the latter.
Methods
Geographic and demographic context
The study was performed at Locarno community hospital, a
250 beds facility entirely dedicated to COVID-19 patients
during the SARS-CoV-2 pandemic, and is part of the public
hospital network of southern Switzerland, serving an area of
350,000 inhabitants and being close to the SARS-CoV-2
outbreak epicenter of Northern Italy (Fig. 1). All data of
SARS-CoV-2 patients were collected in a specific standar-
dized institutional database.
Institutional management of intubated SARS-Cov-2
patients
From April 9, 2020 onwards, COVID-19 patients treated in
the intensive care unit (ICU) were systematically evaluated
for SARS-CoV-2 by RT-PCR of nasopharyngeal swabs
(NPS) and lower tracheal aspirates (LTA). After their initial
test, all patients underwent a biweekly LTA RT-PCR ree-
valuation until removal of the endotracheal tube or death or,
according to the literature [10], until two consecutive nega-
tive RT-PCR results (Fig. 2). Furthermore, in selected cases
and in order to prove the true negativity of a single negative
RT-PCR, a viral culture was performed. In the included
patients the results of NPS were also routinely collected.
Patient selection and variables collected
All intubated ICU patients hospitalized at our institution
between April 9 and May 12, 2020 were retrospectively
reviewed. The following variables were routinely collected:
demographic, clinical, laboratory, and microbiological data
on SARS-CoV-2 patients, ICU-specific complications, and
information on management. Mortality was assessed on
May 20, 2020.
Microbiological analyses: RT-PCR and viral cultures
Sampling was performed according to a designed protocol.
Swab samples were immediately inserted into sterile tubes
containing 3 mL UTM-RT® viral transport medium (Copan,
Brescia Italy), LTA were placed into sterile tubes. Both types
of specimens were sent to the microbiology laboratory for
sample processing and viral RNA extraction, which were
performed on the same day. RT-PCR on NPS were per-
formed using the commercial kit SARS-CoV-2 S Gene
VIASURE Real Time PCR detection kit by CerTest BIO-
TEC on BD MAX Instrument (Becton Dickinson, New
Jersey, USA). RNA extracted from LTA were amplified
using a second PCR system based on the protocol published
by Corman et al. [11] with primers and probes produced by
TibMol Biol (Berlin, Germany). The viral load was indicated
as cycle threshold (Ct) value of S gene of SARS-CoV-2
(VIASURE) and E- and RdRP gene, respectively. A positive
and a negative control, as well as internal controls, was
included in the assay, according to the manufacturer’s pro-
tocol. A Ct value of <40 was defined as positive for SARS-
CoV-2 RNA and >40 was defined as negative. Samples with
a Ct value between 37 and 40 were retested, at least twice.
For virus cultures, patient material was precleared by
centrifugation and filtered before inoculation of Vero
CCL81 cells with a dilution series of the patient material.
Cells were observed daily for cytopathic effects (CPE) and
upon detection of CPE or at latest by d7 supernatants were
harvested and tested for the presence of SARS-CoV-2 by
RT-qPCR.
Outcome
The onset of symptoms was used as the starting time point
for the viral clearance process. The date of the first negative
detection of viral RNA (i.e., time to negativity or viral
shedding) was defined as the end time point of viral clear-
ance (see “Results” section).
Statistical analyses
The time to negativity was described using descriptive
statistics (median and IQR). In order to identify risk
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factors for prolonged viral shedding, we used univariate
Cox proportional hazards models. To date, no study
exhaustively investigated risk factors for prolonged viral
shedding and, therefore, we performed multivariate Cox
models including variables that showed p values < 0.20
in the univariate analysis. A hazard ratio (HR) of <1
indicated prolonged viral RNA shedding. In the Cox
models, the proportionality of hazard risks was tested
using Martingale residuals. The graphical of daily risk
for prolonged viral shedding was illustrated using the
hazard rate function from right-censored data using
kernel-based methods [12]. All statistical analyses were
performed with SAS (version 9.4).
Results
Demographic features
According to the study design and selection criteria, 48
intubated SARS-CoV-2 patients were enrolled. Overall, 161
RT-PCR tests of LTA were performed and patients underwent
Fig. 2 Timeline of RT-PCR evaluation according to the institutional
management during the SARS-CoV-2 pandemic. NPS nasopharyngeal
sample, LTA lower tracheal aspirate. Point prevalence: LTA and NPS
were performed at 2 consecutive days in all intubated patients. During
the follow-up NPS were performed only if an NPS was positive during
the point prevalence assessment
Fig. 1 Geographic description of public health hospital network of
Ticino, the Italian speaking canton in the Southern part of Switzerland.
The different community hospitals are shown in the circles. The
Locarno community hospital (SARS-CoV-2 dedicated center) is
shown by the largest red circle
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two to eight evaluations. The median time from onset of
symptoms and the first sampling was 28 days (IQR:
23.5–32.5). Table 1 details the characteristics of the patients.
Twelve patients (25%) patients died until May 20, 2020. At
screening time, 31 patients (65%) showed same results
between NPS and LTA, whereas in 15 patients (31%) LTA
samples were positive and NPS were negative.
Evaluation of single negative RT-PCR as predictor of
second negative test
In total, 31 patients with one negative RT-PCR in LTA
during their follow-up and 28 (90.3%) had a second negative
test within the following 3 days. Two of the remaining three
cases had a negative test within 1 week. In one case, the
subsequent RT-PCR was positive with 37-Ct. Among these
31 patients, data on the viral culture of LTA samples were
available in four cases at their time of first negative RT-PCR
and all these patients had both negative RT-PCR and culture
results. Overall, we observed that the association of the first
negative RT-PCR with a second negative result was 96.7%.
Analysis of viral shedding
Based on the above results, we are confident that a single
negative RT-PCR in LTA can serve as a proof of negativity.
Median viral shedding was 25 (IQR 21.5–28) days since
symptoms’ onset (Table 1).
Risk factors for prolonged viral shedding
In the univariate Cox model analysis, type 2 diabetes mellitus
was associated with a prolonged viral RNA shedding (HR:
0.41, 95% CI: 0.06–3.11, p= 0.04, Table 2 and Fig. 3).
On the contrary, lymphopenia duration (HR: 0.98, 95%
CI: 0.94–1.01, p= 0.23), ventilator-associated pneumonia
(VAP) during ICU stay (HR: 1.33, 95% CI: 0.38–1.66,
p= 0.54), severe ARDS (HR: 0.59, 95% CI: 0.25–1.39,
p= 0.23), and antivirals (HR: 0.63, 95% CI: 0.30–1.33, p
= 0.23) did not significantly influence the duration of viral
shedding. Also in the multivariate Cox model analysis type
2 diabetes mellitus was associated with a prolonged viral
RNA shedding (HR: 0.31, 95% CI: 0.11–0.89, p= 0.029,
Table 2), and similar results were observed in a sensitivity
analysis defining negativity using two negative LTA sam-
ples (HR: 0.23, 95% CI: 0.07–0.69, p= 0.0089, Table 3).
Of note, the mortality was higher among type 2 diabetes
patients (54 versus 14%, p < 0.01).
Discussion
This study highlighted two important points concerning
viral shedding in critically ill COVID-19 patients: (1) type 2
diabetes mellitus is associated with prolonged SARS-CoV-2
shedding; (2) a first negative LTA sample is predictive for a
second negative sample.
Table 1 Patients’ characteristics
Feature
Age
Median (IQR) 66.5 [60; 71]
Sex
Female n (%) 11 (22.9)
Comorbidities, n (%) 38 (79.2)
Cardiovascular, n (%) 14 (29.2)
Chronic respiratory failure, n (%) 6 (12.5)
Chronic renal insufficiency, n (%) 3 (6.3)
Active solid or hematologic neoplasia, n (%) 4 (8.3)
Type 2 diabetes mellitus, n (%) 13 (27.1)
Hypertension, n (%) 24 (50)
BMI median (IQR), n (%) 29 [25; 33]
Chronic immunosuppression, n (%) 1 (2.1)
Symptoms at admission
Fever, n (%) 44 (91.7)
Cough, n (%) 35 (72.9)
Fatigue, n (%) 29 (60.4)
Diarrhea, n (%) 11 (22.9)
Vomiting, n (%) 5 (10.4)
Antivirals 27 (56.3)
Lopinavir/ritonavir, n (%) 20 (41.7)
Hydroxychloroquine, n (%) 21 (43.8)
Remdesivir, n (%) 7 (14.6)
Tocilizumab, n (%) 5 (10.4)
Laboratory at admission
Lymphocyte 109/L, median (IQR) 0.7 [0.6; 0.9]
Thrombocyte 109/L, median (IQR) 166 [148.5; 186.5]
CRP mg/L, median (IQR) 95.5 [53; 193.5]
Creatinine umol/L, median (IQR) 95.5 [81.5; 123]
Lymphopenia duration, days median (IQR) 24.5 [18.5; 32]
Reasons for ICU admission
Acute respiratory failure, n (%) 46 (95.8)
Sepsis or septic shock, n (%) 1 (2.1)
Cardiac failure, n (%) 1 (2.1)
SAPS II at ICU admission
Median (IQR) 47 [39.5; 58.5]
Severe ARDS, n (%) 36 (75)
Noninfectious complications during ICU stay
Thrombosis, n (%) 25 (52.1)
Acute kidney injury, n (%) 22 (45.8)
Infectious complications during ICU stay
VAP, n (%) 33 (68.8)
UTI, n (%) 10 (20.8)
Candidemia, n (%) 5 (10.4)
Corticosteroids during ICU stay, n (%) 25 (52.1)
Time to negativity, days median (IQR) 25 [21.5; 28]
Mortality, n (%) 12 (25)
IQR interquartile range, BMI body mass index, ICU intensive care
unit, SAPS Simplified Acute Physiology Score, VAP ventilator-
associated pneumonia, UTI urinary tract infection
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Type 2 diabetes patients are at the highest risk for
complications from COVID-19 infection and several
authors described the relationship between COVID-19 and
diabetes [13, 14]. We showed that type 2 diabetes mellitus
was identified as a risk factor for prolonged SARS-CoV-2
shedding. We suggest the following possible pathophysio-
logical explanations: (1) the innate immune system is the
first line of defense against SARS-CoV-2, and may be
compromised in patients with uncontrolled type 2 diabetes
[15, 16]; (2) patients with type 2 diabetes mellitus may be
more susceptible to an inflammatory cytokine storm even-
tually leading to rapid deterioration of COVID-19 [17] and
Table 2 Univariate and
multivariate Cox models for
time to negativity
Univariate model Multivariate modela
HR 95% CI p value HR 95% CI p value
Age 1.04 0.99–1.09 0.14 1.05 0.995–1.12 0.071
Sex, female 1.78 0.81–3.93 0.15 1.35 0.58–3.12 0.490
Comorbidities 0.64 0.27–1.53 0.32
Cardiovascular disease 0.85 0.4–1.82 0.68
Type 2 diabetes mellitus 0.41 0.17–0.97 0.04 0.313 0.11–0.89 0.029
Hypertension 1.23 0.59–2.56 0.58
BMI 1.03 0.97–1.09 0.38
Chronic respiratory failure 0.69 0.25–1.86 0.46
Chronic renal failure 0.42 0.06–3.11 0.40
Solid or hematologic neoplasia 2.08 0.62–6.99 0.24
Lymphopenia duration 0.98 0.94–1.01 0.23
SAPS II at ICU admission 1.01 0.99–1.03 0.42
ARDS, severe 0.59 0.25–1.39 0.23
Thrombosis during ICU stay 1.33 0.64–2.77 0.44
AKI during ICU stay 0.60 0.29–1.25 0.17 1.09 0.48–2.52 0.84
VAP during ICU stay 0.80 0.38–1.66 0.54
UTI during ICU stay 1.10 0.47–2.59 0.82
Colitis during ICU stay 2.56 0.33–19.6 0.37
Corticosteroids during ICU stay 1.10 0.54–2.24 0.80
Antivirals 0.63 0.30–1.33 0.23
Tocilizumab 1.40 0.41–4.72 0.59
The proportionality hazard was assessed using Martingale residuals and was respected for diabetes mellitus
(p= 0.38)
HR hazard ratio, CI confidence interval, BMI body mass index, SAPS Simplified Acute Physiology Score,
ICU intensive care unit, VAP ventilator-associated pneumonia, UTI urinary tract infection, AKI acute kidney
insufficiency
aVariables included in the multivariate analysis were age, sex, type 2 diabetes mellitus, and AKI during
ICU stay
Fig. 3 Estimated hazard rate for type 2 diabetes mellitus and time to
negativity based on univariate Cox model
Table 3 Multivariate Cox analysis using two negative LTA samples
for negativity
Multivariate analysis
HR 95% CI p value
Age 1.05 0.99–1.105 0.080
Sex, female 1.52 0.64–3.63 0.35
Type 2 diabetes mellitus 0.23 0.07–0.69 0.0089
AKI during ICU stay 1.41 0.59–3.36 0.44
HR hazard ratio, CI confidence interval, ICU intensive care unit,
AKI acute kidney insufficiency, LTA lower tracheal aspirate
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to reduced control of viral shedding; (3) type 2 diabetes
mellitus reduced the expression of angiotensin-converting
enzyme 2 which may play a potent anti-inflammatory and
antioxidant role in the lung and, probably, may prolong
viral shedding [18]. Therefore, critically ill people with type
2 diabetes who are infected with COVID-19 may require a
prolonged infection prevention measures during the hospi-
talization. Interestingly, corticosteroid therapy during ICU
stay, VAP, antiviral therapy, lymphopenia, and severe
ARDS did not significantly influence the duration of viral
shedding in our study population.
The ECDC recommends two consecutive negative RT-
PCR tests from respiratory specimens at 24 h interval at least
8 days after symptoms onset to discontinue isolation pre-
cautions in hospitalized COVID-19 patients [10]. Similar
recommendations were issued by several institutions in other
continents [5, 19]. Specimens were usually collected in the
upper respiratory tract, and data on lower respiratory samples
are rarely considered. Viral shedding from upper respiratory
tract appeared to be higher soon after symptoms’ onset;
however, during the course of disease, viral shedding is pre-
dominantly located in the lower respiratory tract [1]. Using
lower respiratory tract samples, we showed that one negative
RT-PCR LTA sample is sufficient to confirm the absence of
viral shedding in critically ill intubated COVID-19 patients,
and the results of RT-PCR were also confirmed in selected
patients by viral cell cultures. These findings highlight the
importance of virological monitoring of LTA samples in
critically ill patients to decide when isolation precautions for
the prevention of respiratory infections could be discontinued,
thus making an early transfer to general wards possible, and
encouraging an early rehabilitation program that may accel-
erate the discharge at home and the reintegration into society.
Our study has several limitations. First, we performed an
observational study using surveillance data. Second, LTA
samples were not collected on a daily basis. Third, viral cell
cultures were not routinely performed during the study. It is
therefore conceivable that the results on viral shedding
might have been different if this method would have been
used systematically. Third, due to the relatively small
sample size, the statistical analyses should be interpreted
with caution. Finally, we did not collect further LTA sam-
ples after two negative results.
Intubated patients with type 2 diabetes mellitus may have
prolonged SARS-CoV-2 shedding. In critically ill COVID-
19 patients, one negative LTA should be sufficient to assess
and exclude infectivity.
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